Travere FDA Approves FILSPARI, Shares Jump 44%

Travere Therapeutics shares jumped 44% after FDA approved FILSPARI for focal segmental glomerulosclerosis (FSGS).
FILSPARI is the first FDA‑approved therapy for FSGS, expanding its label from IgA nephropathy to a second rare kidney disease.
Phase‑3 DUPLEX trial showed 46% proteinuria reduction versus 30% with irbesartan, and 1.1 mL/min/1.73 m² eGFR gain.
Guggenheim analyst Vamil Divan raised price target to $54 from $49, maintaining a Buy rating.